Adebrelimab

DB16412InvestigationalProtein Based Therapies

Adebrelimab is under investigation in clinical trial NCT03711305 (Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-stage (ES) Small Cell Lung Cancer (SCLC)).

Mechanism: Pharmacologically active on Programmed cell death 1 ligand 1
Curator reviewed
Also known as: Adebelizumab
Code names: HTI-1088 · SHR-1316

Resolves to

Compound

UNII1XBY50W1OXCAS2247114-85-6

Targets

Q9NZQ7CD274

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

270Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Adebrelimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account